International Medical Case Reports Journal (Oct 2023)
A Case of Tumor-Induced Osteomalacia Detected by Venous Sampling
Abstract
Yasuo Horinouchi, Seiji Shiota, Ryo Kaimori, Katsuhiko Yoshimura, Rie Utsunomiya-Nishimizu, Kyoko Yamamoto, Eishi Miyazaki Department of General Medicine, Oita University Faculty of Medicine, Yufu, Oita, 879-5593, JapanCorrespondence: Seiji Shiota, Department of General Medicine, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan, Tel +81-97-586-5106, Fax +81-97-586-5573, Email [email protected]: Tumor-induced osteomalacia (TIO) can cause osteomalacia due to excessive production of fibroblast growth factor 23 (FGF23) by the tumor. Since TIO is a very rare disease, it is often misdiagnosed as intervertebral disc herniation, spondyloarthritis, or osteoporosis. We report a 65-year-old man who developed generalized arthralgia and difficulty walking two years ago and was diagnosed with multiple fractures throughout his body. He was initially diagnosed with osteoporosis and was treated with calcitriol. However, he was referred to our hospital since his symptoms did not improve. We diagnosed tumor-induced osteomalacia based on low serum phosphorus, high bone-type alkaline phosphatase, high FGF23 levels, and the presence of two tumors. The responsible tumor was identified using FGF23 levels in venous sampling. As the location of the tumor made surgical resection difficult, we selected treatment with burosumab, a human monoclonal antibody against FGF23, leading to improvement in the hypophosphatemia and pain, such that he was able to walk with a cane. In cases of osteoporosis with hypophosphatemia, general physicians should keep TIO in mind, and attempt to identify the responsible tumor lesion.Keywords: hypophosphatemia, TIO, FGF23, burosumab
